Available online 22 February 2022
–
—
Résumé
Recent data have made it possible to clarify certain aspects in the treatment of anaphylaxis: dosages and pharmacokinetic data of adrenaline auto-injectors, interest of a dosage of 100 μg intended for infants, absence of proof of benefit of corticosteroids in emergency treatment, management of perioperative anaphylaxis, potential use of biotherapies in prevention or as adjuvant treatment of anaphylaxis. In France, recent data in the treatment of anaphylaxis concern the updating of the action to be taken in the event of allergy and the circular individualized reception project since April 2021 and by equipping with auto-injectors of adrenaline from secondary schools (colleges and high schools) since 2019. This article aims to clarify the most recent data in the treatment of anaphylaxis.
—
Abstract
Recent published data have given information on the treatment of anaphylaxis: dosage and pharmacokinetics data on adrenaline autoinjectors, availability of a 100 μg adrenaline autoinjector, lack of evidence of the effectiveness of oral corticosteroids in anaphylaxis, management of perioperative allergic reactions, use of biologicals as preventive or adjunctive treatment of anaphylaxis. In France, recent data concern the update of the emergency action plan for allergic reactions and individual healthcare plan for allergic children at school since April 2021, and provision of spare adrenaline autoinjectors in all high schools since 2019. This article aims at reviewing the most recent data on anaphylaxis treatment.
—
Key words
Anaphylaxis
Adrenaline
adrenaline auto-injector
Child
Individualized reception project
–
Keywords
Adrenaline
Adrenaline autoinjector
Allergy
Anaphylaxis children
Food
Individual healthcare plan
School
—
View full text
© 2022 Elsevier Masson SAS. All rights reserved.
—
